WBC‐reduced platelet concentrates from pooled buffy coats in additive solution: an evaluation of in vitro and in vivo measures

Meer, Pieter F. van der; Pietersz, R. N. I.; Tiekstra, Margriet J.; Huijgens, Peter C.; Dekker, W.J.A.; Reesink, H. W.

doi:10.1046/j.1537-2995.2001.41070917.x

Cited by 22 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The platelet content of the products was measured directly after production, because a previous study has shown a limited decline in platelet number during 5 days of storage. 4,23 We found significant differences with regard to pH and platelet content of the 2 PCs. The lower pH of PAS II PCs is due to a lower intrinsic pH of PAS II, lower buffering capacity, and higher lactate production.…”

Section: Discussionmentioning

confidence: 72%

“…The lower pH of PAS II PCs is due to a lower intrinsic pH of PAS II, lower buffering capacity, and higher lactate production. 23 The lower platelet content of PAS II PCs can be explained by a viscosity-related difference in the platelet distribution during centrifugation, resulting in a less efficient separation. 23 We showed that the 1-and 24-hour CCIs of PAS II PCs were lower compared with plasma PCs, with a mean difference of 19.7% and 17.8%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…22,23 After collection of a unit of whole blood, BCs were prepared through high-speed centrifugation. Five BCs together with 1 unit of PAS II or 1 unit plasma from one of the BC donors were coupled to a BC pool set (containing a transfer bag, leukocyte filter, and a PL-2410 storage container; Baxter) through a sterile connection device.…”

Section: Platelet Concentratesmentioning

confidence: 99%

See 2 more Smart Citations

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma

Kerkhoffs

Eikenboom

Schipperus

et al. 2006

Blood

111

121

View full text Add to dashboard Cite

Randomized studies testing the clinical efficacy of platelet additive solutions (PASs) for storage of platelets are scarce and often biased by patient selection. We conducted a multicenter, randomized study to investigate clinical efficacy of platelets stored in PAS II versus plasma, also including patients with clinical complications associated with increased platelet consumption. A total of 168 evaluable patients received pooled buffy coatderived platelet concentrates (PCs) suspended in either plasma (n ‫؍‬ 354) or PAS II (n ‫؍‬ 411) stored up to 5 days. Both univariate as well as multivariate analysis showed a significant effect of used storage medium in regard to 1-and 24-hour count increments and corrected count increments, in favor of plasma PCs. However, there were no significant differences between the groups regarding bleeding complications and transfusion interval. Adverse transfusion reactions occurred significantly less after transfusions with PAS II PCs (P ‫؍‬ .04). Multivariate analysis showed no significant effect of the used storage medium on the incidence of 1-and 24-hour transfusion failure. We showed safety and efficacy of PAS II PCs in intensively treated patients; however, plasma PCs show superior increments. (Blood. 2006;108:3210-3215)

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Platelet Concentratesmentioning

confidence: 99%

See 1 more Smart Citation

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma

Kerkhoffs

Eikenboom

Schipperus

et al. 2006

Blood

111

121

View full text Add to dashboard Cite

show abstract

“…Prestorage leukocyte depletion is recommended (within 6 hours after preparation if performed by filtration). [23][24][25] The three products may be stored in an additive solution to minimize the risk of transfusion reactions associated with plasma proteins and prevent the risk of transfusion-related acute lung injury. 26 Cryopreserved platelets are prepared by the freezing of platelet concentrates at À80°C within 24 hours of collection using a cryoprotectant (dimethyl sulfoxide 6% weight/ volume or glycerol 5% weight/volume).…”

Section: Platelet Concentratesmentioning

confidence: 99%

Quality of Transfusion Products in Blood Banking

Franchini¹,

Capuzzo²,

Turdo³

et al. 2014

Semin Thromb Hemost

View full text Add to dashboard Cite

The primary goal in transfusion medicine and cellular therapies is to promote high standards of quality and produce ever safer and more efficacious products. The establishment of a transfusion service quality management system, which includes several organizational structures, responsibilities, policies, processes, procedures, and resources, is now mandatory and widely regulated worldwide. In this review, we summarize the current knowledge on the quality system in transfusion medicine as applied to the production of blood components, including red blood cells, platelets, and fresh frozen plasma.

show abstract

“…3 The advantages of using a PAS for platelet storage are many including more plasma to meet patient needs or to fractionate into plasma-based products, reduce red cell hemolysis from ABO incompatible plasma, and reduce other adverse effects related to plasma transfusion. 4,5 To license platelets based on poststorage radiolabeled autologous platelet viability measurements in normal subjects, the US Food and Drug Administration (FDA) requires that the lower poststorage 95% confidence limits (LCLs) for platelet recoveries are $66% and survivals are $58% of the same subject's radiolabeled fresh recoveries and survivals, respectively.…”

Section: Introductionmentioning

confidence: 99%

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Slichter

Corson

Jones

et al. 2014

Blood

View full text Add to dashboard Cite

• Extended apheresis platelet storage is dependent on the collection method, storage in a storage solution, and storage bag composition.• The lifespan of the platelet is not intrinsic to the cell, and platelet viability is better maintained in vitro than in vivo.To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% platelet additive solution (PAS)/20% plasma, 117 healthy subjects donated platelets using the Haemonetics MCS1, COBE Spectra (Spectra), or Trima Accel (Trima) systems. Control platelets from the same subjects were compared with their stored test PAS platelets by radiolabeling their stored and control platelets with either 51 chromium or 111 indium. Trima platelets met Food and Drug Administration poststorage platelet viability criteria for only 7 days vs almost 13 days for Haemonetics platelets; ie, platelet recoveries after these storage times averaged 44 6 3% vs 49 6 3% and survivals were 5.4 6 0.3 vs 4.6 6 0.3 days, respectively. The differences in storage duration are likely related to both the collection system and the storage bag. The Spectra and Trima platelets were hyperconcentrated during collection, and PAS was added, whereas the Haemonetics platelets were elutriated with PAS, which may have resulted in less collection injury. When Spectra and Trima platelets were stored in Haemonetics' bags, poststorage viability was significantly improved. Platelet viability is better maintained in vitro than in vivo, allowing substantial increases in platelet storage times. However, implementation will require resolution of potential bacterial overgrowth during storage. (Blood. 2014;123(2):271-280)

show abstract

WBC‐reduced platelet concentrates from pooled buffy coats in additive solution: an evaluation of in vitro and in vivo measures

Abstract: The WBC-reduced PCs conformed to specifications. These WBC-reduced PCs could be stored at least 5 days with maintenance of pH, and they gave sufficient increments after transfusion to patients.

Cited by 22 publications

References 17 publications

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma

Quality of Transfusion Products in Blood Banking

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Contact Info

Product

Resources

About